Follow
Emma Hansson
Emma Hansson
Pharmetheus
Verified email at pharmetheus.com
Title
Cited by
Cited by
Year
PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST
EK Hansson, MA Amantea, P Westwood, PA Milligan, BE Houk, J French, ...
CPT: pharmacometrics & systems pharmacology 2 (11), 1-9, 2013
672013
PKPD modeling of predictors for adverse effects and overall survival in sunitinib‐treated patients with GIST
EK Hansson, G Ma, MA Amantea, J French, PA Milligan, LE Friberg, ...
CPT: pharmacometrics & systems pharmacology 2 (12), 1-9, 2013
532013
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
EK Hansson, LE Friberg
Cancer chemotherapy and pharmacology 69, 881-890, 2012
372012
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
EK Hansson, JE Wallin, H Lindman, M Sandström, MO Karlsson, ...
Cancer chemotherapy and pharmacology 65, 839-848, 2010
302010
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
Y Tomita, E Hansson, F Mazuir, GJ Wellhagen, QX Ooi, E Mezzalana, ...
Clinical and translational science 15 (4), 1014-1026, 2022
132022
Caplacizumab model‐based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura
M Bergstrand, E Hansson, B Delaey, F Callewaert, R De Passos Sousa, ...
The Journal of Clinical Pharmacology 62 (3), 409-421, 2022
122022
Pharmacometric Models for Biomarkers, Side Effects and Efficacy in Anticancer Drug Therapy
EK Hansson
Acta Universitatis Upsaliensis, 2012
62012
PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3 and sKIT as biomarkers of tumor response and overall survival following sunitinib treatment in GIST
EK Hansson, P Westwood, M Amantea, J French, B Houk, PA Milligan, ...
Annual Meeting of the Population Approach Group in Europe (PAGE), 2011
32011
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and …
RJ Svensson, QX Ooi, LE Friberg, N Maharaj, PK Reddy, L López‐Lázaro, ...
CPT: Pharmacometrics & Systems Pharmacology 12 (2), 154-167, 2023
22023
PKPD-modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib
E Schindler, P Westwood, M Amantea, EK Hansson, PA Milligan, ...
PAGE Meeting, 2012
22012
PS1487 EFFECT OF PLASMA EXCHANGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CAPLACIZUMAB
L Sargentini, E Hansson, M Bergstrand, F Callewaert, R Sousa
HemaSphere 3, 685, 2019
12019
PB2249 CAPLACIZUMAB MODEL-BASED DOSING RECOMMENDATIONS IN PEDIATRIC PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
L Sargentini, E Hansson, M Bergstrand, F Callewaert, R Sousa
HemaSphere 3 (S1), 1007, 2019
12019
The standard treatment protocol is inadequate following overdose of extended release paracetamol: a pharmacokinetic and clinical analysis of 53 cases
H Salmonson, G Sjoberg, J Brogren, E Hansson
CLINICAL TOXICOLOGY 54 (4), 424-424, 2016
12016
Rituximab PK and PKPD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity.
RJ Svensson, QX Ooi, LE Friberg, N Maharaj, PK Reddy, L López-Lázaro, ...
CPT: Pharmacometrics & Systems Pharmacology, 2022
2022
Modelling of Chemotherapy-induced Febrile Neutropenia using the Predicted Degree and Duration of Myelosuppression EK Hansson (1), M. Sandström (2), H. Lindman (3), LE Friberg …
E Hansson
2007
The system can't perform the operation now. Try again later.
Articles 1–15